$0.54
5.40% yesterday
Nasdaq, Apr 03, 10:00 pm CET
ISIN
US09061H3075
Symbol
BMRA

Biomerica, Inc. Stock price

$0.54
-0.17 24.47% 1M
+0.21 63.03% 6M
+0.24 79.27% YTD
-0.30 35.52% 1Y
-4.15 88.53% 3Y
-6.06 91.85% 5Y
-0.20 27.32% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.03 5.40%
ISIN
US09061H3075
Symbol
BMRA
Sector

Key metrics

Market capitalization $9.87m
Enterprise Value $8.13m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.46
P/S ratio (TTM) P/S ratio 1.77
P/B ratio (TTM) P/B ratio 1.93
Revenue growth (TTM) Revenue growth 1.39%
Revenue (TTM) Revenue $5.58m
EBIT (operating result TTM) EBIT $-5.89m
Free Cash Flow (TTM) Free Cash Flow $-5.00m
Cash position $2.37m
EPS (TTM) EPS $-0.33
Short interest 3.60%
Show more

Is Biomerica, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Biomerica, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Biomerica, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Biomerica, Inc.:

Buy
100%

Financial data from Biomerica, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Nov '24
+/-
%
5.58 5.58
1% 1%
100%
- Direct Costs 4.98 4.98
8% 8%
89%
0.60 0.60
33% 33%
11%
- Selling and Administrative Expenses 4.94 4.94
5% 5%
89%
- Research and Development Expense 1.16 1.16
29% 29%
21%
-5.50 -5.50
8% 8%
-99%
- Depreciation and Amortization 0.39 0.39
11% 11%
7%
EBIT (Operating Income) EBIT -5.89 -5.89
7% 7%
-106%
Net Profit -5.61 -5.61
8% 8%
-101%

In millions USD.

Don't miss a Thing! We will send you all news about Biomerica, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biomerica, Inc. Stock News

Neutral
GlobeNewsWire
about one month ago
IRVINE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global leader in advanced medical diagnostic solutions, is proud to announce that its food intolerance products for Crohn's Disease and Ulcerative Colitis have achieved CE-marking under the European Union's new In Vitro Diagnostic Medical Devices Regulation (IVDR – 2017/746).
Neutral
GlobeNewsWire
about one month ago
IRVINE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global leader in advanced medical diagnostic solutions, is proud to announce that patients with Irritable Bowel Syndrome (IBS) may experience significant relief from abdominal pain when following a dietary therapy created and guided by the inFoods® IBS blood test. The findings from a clinical trial published in ...
Neutral
GlobeNewsWire
3 months ago
- 10-Minute PSA Test for Early Detection of Prostate Specific Antigen (PSA), an Early Warning Sign of Prostate Cancer
More Biomerica, Inc. News

Company Profile

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. It focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other Foreign. The company was founded in September 1971 and is headquartered in Irvine, CA.

Head office United States
CEO Zackary Irani
Employees 64
Founded 1971
Website www.biomerica.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today